Dementia with Lewy bodies (DLB) is a clinical syndrome characterized by the presence of Lewy body disease (LBD), but additional Alzheimer's disease (AD)-related pathology is also common in patients with DLB. Although the impact of each of these two pathologies on the clinical disease progression is not fully understood, many DLB patients may benefit from treatments that target both AD and LBD-related pathological processes. To prepare for these clinical trials in DLB, we need robust and reliable biomarkers that can track disease progression, particularly the progression of both LBD- and AD-related pathologies. We propose multi-modal imaging biomarkers of pathological processes commonly present in patients with DLB to detect disease progression. We propose to establish a longitudinal cohort of patients with DLB and acquire clinical and multi-modal imaging biomarker data to model the longitudinal imaging biomarker changes with respect to clinical disease progression in DLB.
In Aim 1, we propose to determine whether LBD-related dopaminergic loss on SPECT, and AD pathophysiology measured with higher amyloid-? deposition on PET and AD-signature atrophy on MRI is associated with the rate of clinical disease progression, cognitive decline and survival in DLB;
In Aim 2, we will determine whether these longitudinal changes in imaging biomarkers and clinical outcomes, and their associations are modified by genetic, sex- based, and cerebrovascular disease-related features.
In Aim 3, we will determine the pattern of a tau ligand AV-1451 uptake in DLB compared to controls and its relationship to the rate of change in imaging biomarkers and clinical disease progression. Finally, we will determine the pathologic basis of the biomarker changes in DLB in autopsied patients, which is the gold standard for validating imaging biomarkers in Aim 4. In addition to these aims that focus on hypothesis testing, we will respond to RFA-NS- 16-022 by collecting whole blood, plasma, serum, CSF, and urine samples, clinical and harmonized neuroimaging data longitudinally; DNA and peripheral blood mononuclear cells from a prospective cohort of DLB patients, and submit them to the PDBP.

Public Health Relevance

Dementia with Lewy bodies (DLB) is a dementia syndrome that is often influenced by both Lewy body disease (LBD) and Alzheimer's disease (AD) pathologies. Determining the autopsy-confirmed multi-modal imaging biomarkers of AD and LBD that are associated with disease progression, survival and treatment response in probable DLB is critical for clinical trials that target specific disease processes in DLB patients.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZNS1)
Program Officer
Babcock, Debra J
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Lowe, Val J; Bruinsma, Tyler J; Min, Hoon-Ki et al. (2018) Elevated medial temporal lobe and pervasive brain tau-PET signal in normal participants. Alzheimers Dement (Amst) 10:210-216
Lowe, Val J; Wiste, Heather J; Senjem, Matthew L et al. (2018) Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia. Brain 141:271-287
Jung, Youngsin; Jordan 3rd, Lennon G; Lowe, Val J et al. (2018) Clinicopathological and 123I-FP-CIT SPECT correlations in patients with dementia. Ann Clin Transl Neurol 5:376-381
Lowe, Val J; Lundt, Emily S; Senjem, Matthew L et al. (2018) White Matter Reference Region in PET Studies of 11C-Pittsburgh Compound B Uptake: Effects of Age and Amyloid-? Deposition. J Nucl Med 59:1583-1589
Jack Jr, Clifford R; Wiste, Heather J; Schwarz, Christopher G et al. (2018) Longitudinal tau PET in ageing and Alzheimer's disease. Brain 141:1517-1528
Ferman, Tanis J; Aoki, Naoya; Crook, Julia E et al. (2018) The limbic and neocortical contribution of ?-synuclein, tau, and amyloid ? to disease duration in dementia with Lewy bodies. Alzheimers Dement 14:330-339
St Louis, Erik K; Boeve, Bradley F (2017) REM Sleep Behavior Disorder: Diagnosis, Clinical Implications, and Future Directions. Mayo Clin Proc 92:1723-1736
Jones, David T; Graff-Radford, Jonathan; Lowe, Val J et al. (2017) Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum. Cortex 97:143-159
Turcano, Pierpaolo; Mielke, Michelle M; Josephs, Keith A et al. (2017) Clinicopathologic discrepancies in a population-based incidence study of parkinsonism in olmsted county: 1991-2010. Mov Disord 32:1439-1446